2024
HAII Secures MFDS Approval for Confirmatory Clinical Trials of Dementia Diagnostic Digital Device
HAII becomes the first in South Korea to receive MFDS approval for clinical trials of its diagnostic digital device, Alzguard, which uses digital biomarkers like voice, eye movement, and cognitive response for early detection.
2024
HAII HAII’s ‘Alzguard-T’ Selected as an Innovation Product by the Public Procurement Service
HAII’s cognitive function evaluation and improvement service, Alzguard-T, was chosen as an innovation product by Korea’s Public Procurement Service, designed to help prevent dementia through brain tests and training for older adults.
2024
HAII Highlights Role of Explainable AI in Digital Health at XAI Workshop 2024
At the ‘KCC XAI Workshop 2024,’ HAII presented its advancements in digital therapeutics, showcasing how explainable AI enhances patient trust and clinical outcomes, particularly through its speech therapy app, “Repeech,” which leverages XAI for improved transparency and personalized treatment.
2023
LG H&H Improves Employees’ Ability to Handle Anxiety and Stress with HAII’s Solution
HAII has signed a contract to supply LG H&H with its mental health app, “Mind Garden 3.0,” based on the digital therapeutic Anzeilax, aiming to enhance employees’ stress management through personalized solutions and digital biomarkers.
2022
Korea Medical Institute Introduces HAII’s Mental Health Checkup Service ‘Mind Scope’
The Korea Medical Institute has introduced ‘Mind Scope’ service in collaboration with HAII, offering screening for six major mental illnesses and job stress at its seven national centers.
2022
HAII Presents Case Study on HCI-Based Digital Targeted Therapy for Mild Cognitive Impairment
announced the development of “AlzTalk 3.0,” a digital therapy for early detection and cognitive rehabilitation in patients with mild cognitive impairment, at the Korean Dementia Association’s academic conference.
@Copyright 2022. All Right Reserved. Hosted by Imweb
